Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Jul 19, 2016Data Support Continued Development Towards Pivotal Bioequivalence Program for European Registration
Pulmatrix, Inc. (NASDAQ: PULM), today announced positive topline data from a Phase 1 pilot pharmacokinetic bioavailability trial of PUR0200. PUR0200 is a novel dry powder formulation of a...
- Jul 6, 2016In an interview with News Medical, Pulmatrix CEO Robert Clarke explains how innovative dry powders enable drugs to be delivered to the lungs more efficiently
Pulmatrix, Inc. (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs, today announced that Chief Executive Officer Robert Clarke, PhD, has described advances in inhaled...
- Jun 27, 2016
Pulmatrix, Inc., (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs today announced the release of an animated life sciences video [ir.pulmatrix.com] to raise awareness...
- Jun 24, 2016Inclusion in the index will bring greater shareholder awareness of Pulmatrix's progress in developing novel inhaled drugs
Pulmatrix, Inc., (NASDAQ: PULM), a specialty pharmaceutical company developing innovative inhaled drugs, announced today that it was added to the Russell Microcap Index when Russell Investments...
- May 25, 2016PUR0200, a once-daily long acting muscarinic antagonist bronchodilator formulation, was given to healthy volunteers to measure pharmacokinetics and to test for safety.
Pulmatrix (NASDAQ:PULM), a specialty pharmaceutical company developing novel inhaled therapeutic formulations based on the company's proprietary iSPERSE™ technology, has completed a pilot...
